Emcure Pharmaceuticals Q4 Results
- BSE: 544210
- NSE: EMCURE
- ISIN: INE168P01015
- Sector: Biotechnology & Drugs
BSE
1,488.70
29.50 (2.02%)
29.50 (2.02%)Volume5.63 K
Updated: Fri 13 Feb, 2026 | 15:15:49
NSE
1,48526.90 (1.84%)
26.90 (1.84%)Volume2.08 L
Updated: Fri 13 Feb, 2026 | 15:30:03
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Emcure Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 1,833.54 | 2,046.19 | 8.00% | 1,550.71 | 18.24% |
| Depreciation/ Amortization | 96.84 | 104.68 | 0.03% | 90.56 | 6.93% |
| Operating Income | 282.71 | 317.29 | 6.71% | 220.65 | 28.12% |
| Net Income | 188.96 | 230.54 | 22.92% | 115.17 | 64.07% |
| Other Operating Expenses Total | 460.85 | 553.60 | 2.13% | 450.50 | 2.30% |
| Net Income Before Taxes | 260.61 | 313.79 | 13.35% | 166.90 | 56.15% |
| Total Revenue | 2,116.25 | 2,363.48 | 7.83% | 1,771.36 | 19.47% |
| Selling/ General/ Admin Expenses Total | 373.37 | 387.33 | 1.75% | 338.51 | 10.30% |
| Diluted Normalized EPS | 10.39 | 13.64 | 27.95% | 5.39 | 92.78% |